Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
Dr. Reddy's Laboratories is recalling 696 bottles of Ezetimibe and Simvastatin Tablets (10 mg/40 mg) distributed nationwide due to failed excipient specifications and the presence of foreign tablets in bottles.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The hazards—failed excipient specifications and presence of incorrect tablet strengths—represent quality and manufacturing control issues rather than documented harm or high-risk contamination. The recall is precautionary in nature.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Ezetimibe and Simvastatin Tablets, 10 mg/40 mg, 500-count bottles (NDC 43598-743-05, Lot L100208, expiration 01/2023). The recall affects 696 bottles distributed nationwide in the United States.
The product was manufactured using an excipient (an inactive ingredient) that failed to meet conductivity specifications. Additionally, some bottles were found to contain foreign tablets identified as Ezetimibe and Simvastatin 10 mg/10 mg, which are not the correct strength for this recall lot.
Consumers who have received this product should stop taking it and contact their pharmacy or healthcare provider. Patients should not discontinue their cholesterol-lowering medication without medical guidance and should obtain a replacement from their pharmacy or contact Dr. Reddy's Laboratories, Inc. for assistance.
The recalled product
- Product
- EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
- Brand
- EZETIMIBE AND SIMVASTATIN
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Hazard
- failed-excipient-specifications
- foreign-tablets
- manufacturing-control
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- L100208
- exp 01/2023
UPCs (4)
- 0343598745909
- 0343598742908
- 0343598743905
- 0343598744902
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · EZETIMIBE AND SIMVASTATIN
- ModerateEzetimibe and Simvastatin tablets recalled for impurity specification failure
FDA (Drugs) · 2025-06-18
- ModerateEzetimibe and Simvastatin Tablets Recalled for Defective Excipient and Foreign Tablets
FDA (Drugs) · 2021-11-17
- ModerateEzetimibe and Simvastatin Tablets Recalled for Excipient Specification Failure
FDA (Drugs) · 2021-11-17
- ModerateDr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
FDA (Drugs) · 2021-11-10
- ModerateDr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Excipient Specification Failure
FDA (Drugs) · 2021-11-10
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27